The Medical and Surgical Practice of NaProTECHNOLOGY, 345-368, 2004
Chapter 29: Premenstrual Syndrome: Evaluation and Treatment
Author affiliations
- Pope Paul VI Institute for the Study of Human Reproduction, Omaha, Nebraska. ROR
Abstract
Premenstrual syndrome in NaProTECHNOLOGY is defined by a recurrent cluster of symptoms -- including irritability, breast tenderness, bloating, depression, and carbohydrate craving -- beginning at least four days before menses, and is associated with late-luteal deficiencies in progesterone, estrogen, and beta-endorphin identified through CrMS-anchored hormone profiling. Treatment with cycle-synchronized bioidentical progesterone, targeted HCG injections to stimulate endogenous corpus luteum function, and low-dose naltrexone to modulate opioid dynamics produces superior symptom resolution compared to SSRI therapy in Hilgers' comparative data, without suppressing ovulation.
Topics
Cite this article
Hilgers, T. W. (2004). Chapter 29: Premenstrual Syndrome: Evaluation and Treatment. *The Medical and Surgical Practice of NaProTECHNOLOGY*, 345-368.
Hilgers TW. Chapter 29: Premenstrual Syndrome: Evaluation and Treatment. The Medical and Surgical Practice of NaProTECHNOLOGY. 2004:345-368.